Back to top
more

Journey Medical (DERM)

(Delayed Data from NSDQ)

$7.53 USD

7.53
158,078

-0.38 (-4.80%)

Updated Aug 25, 2026 04:00 PM ET

After-Market: $7.51 -0.02 (-0.27%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (150 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Journey Medical Corporation (DERM) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Journey Medical Corporation (DERM), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks Equity Research

Lilly (LLY) Q4 Earnings and Sales Top Estimates, Stock Up

by Zacks Equity Research

Eli Lilly's (LLY) Q4 earnings and sales beat estimates. Shares rise in pre-market trading.

Zacks Equity Research

Lilly (LLY) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are likely to have performed well. Let's see if these along with older products lead to an earnings beat for the company.

Zacks Equity Research

Lilly to Buy Dermira for $1.1B, Add Phase III Eczema Candidate

by Zacks Equity Research

Lilly (LLY) offers to buy Dermira for $1.1 billion to add the latter's late-stage candidate for atopic dermatitis/eczema, lebrikizumab.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Agile Therapeutics, Air Industries, Dermira, Microbot Medical and Cassava Sciences

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Agile Therapeutics, Air Industries, Dermira, Microbot Medical and Cassava Sciences

Tirthankar Chakraborty headshot

Buy Multibagger Stocks as Odds of a Rally Are High in 2020

by Tirthankar Chakraborty

Multibagger stocks can make most of the bull run, courtesy of strong fundamentals and businesses that can multiply in a short span of time.

Zacks Equity Research

Pacira's (PCRX) Exparel Meets Key Goals in C-Section Study

by Zacks Equity Research

Pacira's (PCRX) phase IV CHOICE study on its lead drug Exparel in patients undergoing Cesarean section attains the primary as well as key secondary endpoints.

Zacks Equity Research

Moving Average Crossover Alert: Dermira

by Zacks Equity Research

Dermira, Inc. (DERM) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Zacks Equity Research

Will Dermira Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Dermira.

Zacks Equity Research

The Zacks Analyst Blog Highlights: LHC, Retrophin, Dermira and Merck & Co

by Zacks Equity Research

The Zacks Analyst Blog Highlights: LHC, Retrophin, Dermira and Merck & Co